EUNew treatments and approvals
Trofinetide approved in the EU for behavioral symptoms of Rett syndrome
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
On August 20, 2026, the European Commission approved trofinetide for Rett syndrome. The drug is for behavioral and emotional symptoms in patients aged 5 years and older. It is a liquid that is drunk or given through a stomach tube twice a day. The main study included 187 girls and women. Symptoms were assessed over 12 weeks.
What does it mean for patients and families?
The drug targets the symptoms, not the disease itself. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Rett syndrome
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.